- Home
- / Unicycive Therapeutics
Unicycive Therapeutics
Stock Price
$0.5
2024-10-29
Market Capitalization
$45.5 M
2024-10-29
Revenue
$675 K
FY, 2023
Unicycive Therapeutics Summary
Company Summary
- Overview
- Unicycive Therapeutics is a biotechnology company that develops treatment for kidney diseases with significant unmet medical needs. It focuses on the development of two therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury.
- Type
- Public
- Status
- Active
- Founded
- 2016
- HQ
- Los Altos, CA, US | view all locations
- Website
- https://unicycive.com/
- Cybersecurity rating
Table of Contents
Key People
John Ryan, Director
LocationsView all
1 location detected
Los Altos, CA HQ
United States
5150 El Camino Real suite a - 32
Unicycive Therapeutics Financials
Summary Financials
- Net income (Q1, 2026)
- ($12.8M)
- Cash (Q1, 2026)
- $37.4M
- EBIT (Q1, 2026)
- ($8.4M)
- Enterprise value
- $9.7M